Salesforce, Inc. (NYSE:CRM) is one of the Best Quality Stocks to Buy Before 2026. On December 17, Salesforce, Inc.

Capital is flocking to a few high-growth AI plays and ignoring other opportunities because of the AI trend in the markets.

Long-term investing is easy and relatively stress-free, at least in principle. All you have to do is purchase shares of ...

Salesforce Inc (NYSE:CRM) shares moved higher Wednesday after BTIG kicked off coverage with a Buy rating and a $335 price target, while the company scored a major win with Novartis choosing its ...

In mid-November, to boost domestic drug product manufacturing of its own, Moderna announced 3 a new $140 million investment in its onshore manufacturing that’ll bring its manufacturing capabilities to ...

Corporate and political leaders gathered Thursday for a groundbreaking more symbolic than literal. They were celebrating Novartis Gene Therapies commitment to North Carolina. North Carolina Gov. Josh ...

ORLANDO, Fla.—Novartis is divulging details from ianalumab’s summertime phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could delay the progression of patients to ...

Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases and guide clinical development programs. Months after securing an approval ...

Today, a brief rundown of news from Bristol Myers Squibb, Novartis and Agios Pharmaceuticals, plus Food and Drug Administration officials who are proposing a new framework for testing CAR-T cell ...

Novartis Services, the Swiss-based pharmaceutical company, was hit with a breach-of-contract lawsuit on Dec. 1 in Michigan Circuit Court for Ingham County over allegedly unpaid consulting services.